HLB, a biotech firm, said Tuesday that it would apply for conditional permission for its targeted anticancer drug, rivoceranib. HLB, an affiliate of the HLB Group, holds the domestic sales right of rivoceranib.

According to industry sources, HLB plans to apply to the Ministry of Food and Drug Safety Ministry in the first quarter of next year for the conditional approval of rivoceranib to treat adenocarcinoma based on its phase 2 clinical trials.
 

Please refer to the following website for further details: 

http://www.koreabiomed.com/news/articleView.html?idxno=14991